AK6: A Drug Target and Biomarker for Fasting-Induced Cellular Metabolism

Target Name: AK6

NCBI ID: G102157402

Content of Review Report on AK6 Target / Biomarker

AK6

AK6: A Drug Target and Biomarker for Fasting-Induced Cellular Metabolism

AK6, also known as ATPase, is a protein that plays a crucial role in the regulation of cellular metabolism. It is a customer of the ATPase superfamily, which is a family of proteins that are involved in the transfer of ATP energy to various cellular processes. In this article, we will discuss AK6 as a drug target and biomarker for fasting-induced cellular metabolism.

The Role of AK6 in Cellular Metabolism

AK6 is a 25kDa protein that is expressed in various cell types, including neurons, muscle cells, and liver cells. It is involved in the regulation of cellular metabolism by participating in the ATPase reaction. The ATPase reaction is the process by which the cell generates ATP using the energy from food pyruvate.

In fasted states, the body enters a state of nutrient deprivation, which triggers a variety of cellular responses to adapt to the available energy sources. One of these responses is an increase in the rate of cellular metabolism, as the body tries to maximize the use of the limited nutrients available.

AK6 plays a crucial role in this process by regulating the ATPase reaction to ensure that the cell maximizes the amount of ATP generated from the food pyruvate. Fasting-induced cellular metabolism is a well-established phenomenon that has been observed in various organisms, including humans.

Drug Targeting and Biomarker for Fasting-Induced Cellular Metabolism

The fasted-induced increase in cellular metabolism can be a valuable drug target for the treatment of various diseases. For example, obesity is a major health problem that is associated with an increased risk of various cardiovascular diseases, diabetes, and metabolic disorders.

Research has shown that Fasting-Induced Metabolic Rate (FIMR) is a potential biomarker for the treatment of obesity. FIMR is the rate of metabolism that occurs in the body during periods of starvation. It is increased in individuals with obesity and is associated with an increased risk of disease.

AK6 has been shown to be a potential drug target for the treatment of obesity. Studies have shown that inhibiting the activity of AK6 can reduce the rate of cellular metabolism, which can lead to a decrease in the body's production of ATP. This decrease in ATP can then lead to an increase in the rate of muscle protein synthesis, which can lead to muscle growth and an overall improvement in body composition.

In addition to its potential as a drug target, AK6 has also been shown to be a potential biomarker for fasting-induced cellular metabolism. Fasting-Induced Metabolic Rate (FIMR) is a potential biomarker for FIMR, which is the rate of metabolism that occurs in the body during periods of starvation.

Conclusion

In conclusion, AK6 is a protein that plays a crucial role in the regulation of cellular metabolism, particularly in fasted states. It is a potential drug target for the treatment of obesity and a potential biomarker for fasting-induced cellular metabolism. Further research is needed to fully understand the role of AK6 in cellular metabolism and its potential as a drug target and biomarker.

Protein Name: Adenylate Kinase 6

Functions: Broad-specificity nucleoside monophosphate (NMP) kinase that catalyzes the reversible transfer of the terminal phosphate group between nucleoside triphosphates and monophosphates. AMP and dAMP are the preferred substrates, but CMP and dCMP are also good substrates. IMP is phosphorylated to a much lesser extent. All nucleoside triphosphates ATP, GTP, UTP, CTP, dATP, dCTP, dGTP, and TTP are accepted as phosphate donors. CTP is the best phosphate donor, followed by UTP, ATP, GTP and dCTP. May have a role in nuclear energy homeostasis. Has also ATPase activity. May be involved in regulation of Cajal body (CB) formation

The "AK6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AK6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets